RCUS Valuation

Arcus Biosciences Inc

Add to Watchlist

Advanced Chart

12.520

+0.13(1.049%)1D

Overview
Forecast
Valuation
Earnings

RCUS Relative Valuation

RCUS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RCUS is overvalued; if below, it's undervalued.

Historical Valuation

Arcus Biosciences Inc (RCUS) is now in the Fair zone, suggesting that its current forward PS ratio of 11.58 is considered Fairly compared with the five-year average of -6.54. The fair price of Arcus Biosciences Inc (RCUS) is between 10.83 to 23.25 according to relative valuation methord.

Relative Value

Fair Zone

10.83-23.25

Current Price：12.52

Fair

-2.65

Trailing

Forward

-1.15

EV/EBITDA

Arcus Biosciences Inc. (RCUS) has a current EV/EBITDA of -1.15. The 5-year average EV/EBITDA is -4.15. The thresholds are as follows: Strongly Undervalued below -13.96, Undervalued between -13.96 and -9.06, Fairly Valued between 0.75 and -9.06, Overvalued between 0.75 and 5.66, and Strongly Overvalued above 5.66. The current Forward EV/EBITDA of -1.15 falls within the Historic Trend Line -Fairly Valued range.

-0.94

EV/EBIT

Arcus Biosciences Inc. (RCUS) has a current EV/EBIT of -0.94. The 5-year average EV/EBIT is -3.26. The thresholds are as follows: Strongly Undervalued below -10.38, Undervalued between -10.38 and -6.82, Fairly Valued between 0.31 and -6.82, Overvalued between 0.31 and 3.87, and Strongly Overvalued above 3.87. The current Forward EV/EBIT of -0.94 falls within the Historic Trend Line -Fairly Valued range.

11.58

Arcus Biosciences Inc. (RCUS) has a current PS of 11.58. The 5-year average PS is 14.35. The thresholds are as follows: Strongly Undervalued below 0.10, Undervalued between 0.10 and 7.23, Fairly Valued between 21.48 and 7.23, Overvalued between 21.48 and 28.61, and Strongly Overvalued above 28.61. The current Forward PS of 11.58 falls within the Historic Trend Line -Fairly Valued range.

-3.13

P/OCF

Arcus Biosciences Inc. (RCUS) has a current P/OCF of -3.13. The 5-year average P/OCF is -7.97. The thresholds are as follows: Strongly Undervalued below -45.39, Undervalued between -45.39 and -26.68, Fairly Valued between 10.74 and -26.68, Overvalued between 10.74 and 29.44, and Strongly Overvalued above 29.44. The current Forward P/OCF of -3.13 falls within the Historic Trend Line -Fairly Valued range.

-9.39

P/FCF

Arcus Biosciences Inc. (RCUS) has a current P/FCF of -9.39. The 5-year average P/FCF is -8.46. The thresholds are as follows: Strongly Undervalued below -33.71, Undervalued between -33.71 and -21.08, Fairly Valued between 4.16 and -21.08, Overvalued between 4.16 and 16.79, and Strongly Overvalued above 16.79. The current Forward P/FCF of -9.39 falls within the Historic Trend Line -Fairly Valued range.

Arcus Biosciences Inc (RCUS) has a current Price-to-Book (P/B) ratio of 2.40. Compared to its 3-year average P/B ratio of 2.31 , the current P/B ratio is approximately 3.87% higher. Relative to its 5-year average P/B ratio of 2.72, the current P/B ratio is about -11.78% higher. Arcus Biosciences Inc (RCUS) has a Forward Free Cash Flow (FCF) yield of approximately -25.94%. Compared to its 3-year average FCF yield of -13.13%, the current FCF yield is approximately 97.54% lower. Relative to its 5-year average FCF yield of -5.59% , the current FCF yield is about 364.25% lower.

2.43

P/B

Median3y

2.31

Median5y

2.72

-25.94

FCF Yield

Median3y

-13.13

Median5y

-5.59

Competitors Valuation Multiple

The average P/S ratio for RCUS's competitors is 2.09, providing a benchmark for relative valuation. Arcus Biosciences Inc Corp (RCUS) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 310.26%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

RCUS.N

Arcus Biosciences Inc

Abcellera Biologics Inc

Syndax Pharmaceuticals Inc

Stoke Therapeutics Inc

Xeris Biopharma Holdings Inc

Loss

48.84%

1.27B

Performance Decomposition

Market capitalization of RCUS decreased by 18.12% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 39.00M to 160.00M.

The secondary factor is the Margin Expansion, contributed -100.00%to the performance.

Overall, the performance of RCUS in the past 1 year is driven by Revenue Growth. Which is more sustainable.

310.26%

39.00M → 160.00M

Revenue Growth

-100.00%

-238.46 → 0.00

Margin Expansion

-228.38%

3.17 → -4.07

P/E Change

-18.12%